Addition of radiotherapy to surgery and chemotherapy improves survival in localized malignant pleural mesothelioma: A Surveillance, Epidemiology, and End Results (SEER) study

Malignant pleural mesothelioma (MPM) is a highly aggressive cancer of the visceral or parietal pleura, with greater than 90% of cases occurring in the setting of asbestos exposure. It is a relatively rare cancer, with an incidence of approximately 10 per 1 million person-years in the United States. It has a long latency period, up to 20 years after asbestos exposure, and the median age of diagnosis is 75 years old. [1,2]
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

Malignant pleural mesothelioma (MPM) is a rare but aggressive cancer. The long latency from asbestos exposure to MPM development, as well as the absence of early symptoms, lead to late diagnosis and very poor prognosis, with a life expectancy of 9-18 months from diagnosis [1]. Only a small number of patients is suitable for multimodal therapy, including surgery, and the majority of patients receive palliative chemotherapy.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Patients with pleural mesothelioma cancer may have another treatment option after the U.S. Food and Drug Administration approved the use of pembrolizumab for certain metastatic tumors this week. Pembrolizumab, often known by the brand name Keytruda, is a well-known immunotherapy drug already being used with mixed success for several cancers. This latest FDA approval is for the treatment of adult and pediatric cancers with unresectable disease and high mutational burden that have progressed following prior treatment and have no alternative treatment options. A number of mesothelioma patients already are being treated with p...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
A multicenter research team of specialists has uncovered a surprising underutilization of treatments for pleural mesothelioma cancer in women. Clinical Lung Cancer recently published the findings, which showed a significant sex-based disparity in the receipt of care for women when compared with that of men. Women were 15% less likely to receive aggressive mesothelioma surgery that has proven its worth in extending lives for this cancer, which has no definitive cure. They also were 20% less likely to receive chemotherapy than were men. “This is concerning, absolutely,” Dr. Charles Simone, chief medical officer a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignant tumor primarily affecting the pleura with approximately 80 % of cases resulting from occupational or environmental asbestos exposure [1 –4]. The MPM incidence is suspected to increase in the future in many countries in which asbestos either has not yet been banned or is still largely used. The prognosis of MPM is very poor, with a median survival time between 12 and 18 months and a 5-year survival rate of
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
243Objectives: Despite promising response rates in phase 1b and 2 clinical trials, immune checkpoint inhibition (ICI) with pembrolizumab for the treatment of malignant pleural mesothelioma (MPM) did not result in survival benefit in the PROMISE-meso trial compared to 2nd-line chemotherapy. Due to lack of validated imaging response criteria, responder-subgroups with potential survival benefit have not yet been identified. Here, we assess the predictive value of PET metabolic response in patients undergoing four cycles of high-dose pembrolizumab (10 mg/kg, d1, q2w) considering the KEYNOTE-028 trial procedure for chemotherapy...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Lung Cancer I Source Type: research
Conclusions: Since its introduction, PERCIST 1.0 has been increasingly used in many clinical trials and prospective studies, with variable reporting of metabolic response and survival data. In general, it appears PERCIST response is associated with longer PFS and survival though the heterogeneity of disease, scan timing and therapies make data pooling difficult. Prospective inclusion of the PERCIST 1.0 criteria in clinical trials using FDG, with baseline, early monitoring, and end of therapy scans could inform cancer clinical trials. Support: 5U01CA140204-04 Reference: 1. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: NET and Others II Source Type: research
This study is open also to patients with lung cancer or urothelial cancer. In the trial, the use of cabozantinib will be combined with standard-of-care Alimta, the chemotherapy drug generically known as pemetrexed. The study is designed to establish a safe and effective dosage level for both agents when used together. Cabozantinib is known as an inhibitor. It blocks signals that encourage the growth of new blood vessels needed for cancer cells to divide and grow. Blocking those signals can shrink tumors or even cause tumor cell death, leading to significantly longer survival for patients. Cabozantinib will be taken orall...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Unlike the pleural mesothelioma, direct link to asbestosis in case of primary pericardial mesothelioma has not been established [1]. It is a very rare malignant tumour of the pericardium with around 150 cases reported. Yet it represents half of primary pericardial tumours. It is a malignancy of the mesothelial cells lining the visceral or parietal pericardium. Majority of cases occur between fourth and seventh decade and a male preponderance has been noted. They can present with large pericardial effusions which can be fatal [2]. In general it is an aggressive disease with survival less than 6 months. In one case report, ...
Source: Cardiophile MD - Category: Cardiology Authors: Tags: Cardio Oncology Source Type: blogs
Medical oncologist Dr. Angus Dalgleish never did like standard of care treatment for pleural mesothelioma cancer, even when he reluctantly recommended it in the past. He believes now there is something better. Dalgleish, of St. George’s Hospital, University of London, recently published a case report detailing a novel treatment regimen that turned a six-month life expectancy for one patient into a six-year survival. The treatment involved a series of anti-inflammatories that included low-dose naltrexone, vitamin D3 supplements and the vaccine IMM-101, which heightens a patient’s own immune response. “Init...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
ConclusionsThis study indicated that CT ‐707 is clinically effective as a new antitumor drug for Chinese lung adenocarcinoma patients with ALK rearrangement. It is safe and reliable and the dose‐expansion phase recruitment has started.
Source: Thoracic Cancer - Category: Cancer & Oncology Authors: Tags: ORIGINAL ARTICLE Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Chemotherapy | Epidemiology | Lung Cancer | Mesothelioma | Study | USA Health